{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:20:48Z","timestamp":1790742048229,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-025-00929-y","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T22:55:48Z","timestamp":1743202548000},"page":"682-701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Systemic rewiring of dendritic cells by melanoma-secreted midkine impairs immune surveillance and response to immune checkpoint blockade"],"prefix":"10.1038","volume":"6","author":[{"given":"Xavier","family":"Catena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Contreras-Alcalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6088-5507","authenticated-orcid":false,"given":"Naiara","family":"Juan-Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cerezo-Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonantzin G.","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Mucientes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5513-5621","authenticated-orcid":false,"given":"David","family":"Olmeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6461-4031","authenticated-orcid":false,"given":"Sergio","family":"Oterino-Sogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lola","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0755-0518","authenticated-orcid":false,"given":"Diego","family":"Meg\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2890-3984","authenticated-orcid":false,"given":"David","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Tejedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Frago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Dudziak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1529-3507","authenticated-orcid":false,"given":"Athanasios","family":"Seretis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Stoitzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0612-6299","authenticated-orcid":false,"given":"Mar\u00eda S.","family":"Soengas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"929_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41568-022-00442-9","volume":"22","author":"S Kalaora","year":"2022","unstructured":"Kalaora, S., Nagler, A., Wargo, J. A. & Samuels, Y. Mechanisms of immune activation and regulation: lessons from melanoma. Nat. Rev. Cancer 22, 195\u2013207 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"929_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495\u2013501 (2014).","journal-title":"Nature"},{"key":"929_CR3","doi-asserted-by":"crossref","unstructured":"Wolchok, J. D. et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 392, 11\u201322 (2024).","DOI":"10.1056\/NEJMe2411489"},{"key":"929_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/CCO.0000000000000610","volume":"32","author":"H Herrscher","year":"2020","unstructured":"Herrscher, H. & Robert, C. Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. Curr. Opin. Oncol. 32, 106\u2013113 (2020).","journal-title":"Curr. Opin. Oncol."},{"key":"929_CR5","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1158\/1078-0432.CCR-20-4092","volume":"27","author":"MB Atkins","year":"2021","unstructured":"Atkins, M. B. et al. The state of melanoma: emergent challenges and opportunities. Clin. Cancer Res. 27, 2678\u20132697 (2021).","journal-title":"Clin. Cancer Res."},{"key":"929_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrc.2016.37","volume":"16","author":"AH Shain","year":"2016","unstructured":"Shain, A. H. & Bastian, B. C. From melanocytes to melanomas. Nat. Rev. Cancer 16, 345\u2013358 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"929_CR7","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.2174\/1381612822666160826111041","volume":"22","author":"D Cerezo-Wallis","year":"2016","unstructured":"Cerezo-Wallis, D. & Soengas, M. S. Understanding tumor\u2013antigen presentation in the new era of cancer immunotherapy. Curr. Pharm. Des. 22, 6234\u20136250 (2016).","journal-title":"Curr. Pharm. Des."},{"key":"929_CR8","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ccell.2020.11.015","volume":"39","author":"CS Grasso","year":"2021","unstructured":"Grasso, C. S. et al. Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma. Cancer Cell 39, 500\u2013515 (2021).","journal-title":"Cancer Cell"},{"key":"929_CR9","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nature22977","volume":"546","author":"D Olmeda","year":"2017","unstructured":"Olmeda, D. et al. Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine. Nature 546, 676\u2013680 (2017).","journal-title":"Nature"},{"key":"929_CR10","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1038\/s41591-020-1073-3","volume":"26","author":"D Cerezo-Wallis","year":"2020","unstructured":"Cerezo-Wallis, D. et al. Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. Nat. Med. 26, 1865\u20131877 (2020).","journal-title":"Nat. Med."},{"key":"929_CR11","doi-asserted-by":"publisher","first-page":"1310094","DOI":"10.3389\/fimmu.2023.1310094","volume":"14","author":"EE Neumaier","year":"2023","unstructured":"Neumaier, E. E., Rothhammer, V. & Linnerbauer, M. The role of midkine in health and disease. Front. Immunol. 14, 1310094 (2023).","journal-title":"Front. Immunol."},{"key":"929_CR12","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1038\/s41388-019-1124-8","volume":"39","author":"PS Filippou","year":"2020","unstructured":"Filippou, P. S., Karagiannis, G. S. & Constantinidou, A. Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. Oncogene 39, 2040\u20132054 (2020).","journal-title":"Oncogene"},{"key":"929_CR13","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00262-012-1235-3","volume":"61","author":"S Zhao","year":"2012","unstructured":"Zhao, S. et al. Midkine upregulates MICA\/B expression in human gastric cancer cells and decreases natural killer cell cytotoxicity. Cancer Immunol. Immunother. 61, 1745\u20131753 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"929_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32673-7","volume":"13","author":"Y Tang","year":"2022","unstructured":"Tang, Y., Kwiatkowski, D. J. & Henske, E. P. Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment. Nat. Commun. 13, 5018 (2022).","journal-title":"Nat. Commun."},{"key":"929_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1189\/jlb.3MR1116-475R","volume":"102","author":"N Sorrelle","year":"2017","unstructured":"Sorrelle, N., Dominguez, A. T. A. & Brekken, R. A. From top to bottom: midkine and pleiotrophin as emerging players in immune regulation. J. Leukoc. Biol. 102, 277\u2013286 (2017).","journal-title":"J. Leukoc. Biol."},{"key":"929_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","volume":"21","author":"I Heras-Murillo","year":"2024","unstructured":"Heras-Murillo, I., Adan-Barrientos, I., Galan, M., Wculek, S. K. & Sancho, D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat. Rev. Clin. Oncol. 21, 257\u2013277 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"929_CR17","doi-asserted-by":"publisher","first-page":"101481","DOI":"10.1016\/j.smim.2021.101481","volume":"52","author":"AE Marciscano","year":"2021","unstructured":"Marciscano, A. E. & Anandasabapathy, N. The role of dendritic cells in cancer and anti-tumor immunity. Semin. Immunol. 52, 101481 (2021).","journal-title":"Semin. Immunol."},{"key":"929_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","volume":"580","author":"B Maier","year":"2020","unstructured":"Maier, B. et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature 580, 257\u2013262 (2020).","journal-title":"Nature"},{"key":"929_CR19","doi-asserted-by":"publisher","first-page":"e20200264","DOI":"10.1084\/jem.20200264","volume":"218","author":"GM Gerhard","year":"2021","unstructured":"Gerhard, G. M., Bill, R., Messemaker, M., Klein, A. M. & Pittet, M. J. Tumor-infiltrating dendritic cell states are conserved across solid human cancers. J. Exp. Med. 218, e20200264 (2021).","journal-title":"J. Exp. Med."},{"key":"929_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cell.2017.06.016","volume":"170","author":"CJ Nirschl","year":"2017","unstructured":"Nirschl, C. J. et al. IFN\u03b3-dependent tissue-immune homeostasis is co-opted in the tumor microenvironment. Cell 170, 127\u2013141 (2017).","journal-title":"Cell"},{"key":"929_CR21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.immuni.2016.07.019","volume":"45","author":"L Ardouin","year":"2016","unstructured":"Ardouin, L. et al. Broad and largely concordant molecular changes characterize tolerogenic and immunogenic dendritic cell maturation in thymus and periphery. Immunity 45, 305\u2013318 (2016).","journal-title":"Immunity"},{"key":"929_CR22","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.immuni.2023.05.011","volume":"56","author":"F Bayerl","year":"2023","unstructured":"Bayerl, F. et al. Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. Immunity 56, 1341\u20131358 (2023).","journal-title":"Immunity"},{"key":"929_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-4","volume":"8","author":"P Jin","year":"2010","unstructured":"Jin, P. et al. Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J. Transl. Med. 8, 4 (2010).","journal-title":"J. Transl. Med."},{"key":"929_CR24","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1182\/blood.V96.9.3029","volume":"96","author":"K Brasel","year":"2000","unstructured":"Brasel, K., De Smedt, T., Smith, J. L. & Maliszewski, C. R. Generation of murine dendritic cells from FLT3-ligand-supplemented bone marrow cultures. Blood 96, 3029\u20133039 (2000).","journal-title":"Blood"},{"key":"929_CR25","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/pcmr.12498","volume":"29","author":"K Meeth","year":"2016","unstructured":"Meeth, K., Wang, J. X., Micevic, G., Damsky, W. & Bosenberg, M. W. The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell Melanoma Res. 29, 590\u2013597 (2016).","journal-title":"Pigment Cell Melanoma Res."},{"key":"929_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41423-021-00741-5","volume":"19","author":"TL Murphy","year":"2022","unstructured":"Murphy, T. L. & Murphy, K. M. Dendritic cells in cancer immunology. Cell. Mol. Immunol. 19, 3\u201313 (2022).","journal-title":"Cell. Mol. Immunol."},{"key":"929_CR27","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1164206","volume":"322","author":"K Hildner","year":"2008","unstructured":"Hildner, K. et al. BATF3 deficiency reveals a critical role for CD8\u03b1+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097\u20131100 (2008).","journal-title":"Science"},{"key":"929_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7\u201324 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"929_CR29","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing BATF3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711\u2013723 (2017).","journal-title":"Cancer Cell"},{"key":"929_CR30","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP Bottcher","year":"2018","unstructured":"Bottcher, J. P. et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022\u20131037 (2018).","journal-title":"Cell"},{"key":"929_CR31","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638\u2013652 (2014).","journal-title":"Cancer Cell"},{"key":"929_CR32","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","volume":"24","author":"KC Barry","year":"2018","unstructured":"Barry, K. C. et al. A natural killer\u2013dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat. Med. 24, 1178\u20131191 (2018).","journal-title":"Nat. Med."},{"key":"929_CR33","doi-asserted-by":"publisher","first-page":"e002054","DOI":"10.1136\/jitc-2020-002054","volume":"9","author":"FJ Cueto","year":"2021","unstructured":"Cueto, F. J. et al. DNGR-1 limits FLT3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells. J. Immunother. Cancer 9, e002054 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"929_CR34","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1038\/onc.2013.409","volume":"33","author":"Y Dong","year":"2014","unstructured":"Dong, Y. et al. PTEN functions as a melanoma tumor suppressor by promoting host immune response. Oncogene 33, 4632\u20134642 (2014).","journal-title":"Oncogene"},{"key":"929_CR35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature 523, 231\u2013235 (2015).","journal-title":"Nature"},{"key":"929_CR36","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.3892\/ijo.2012.1665","volume":"41","author":"R Liersch","year":"2012","unstructured":"Liersch, R. et al. Analysis of a novel highly metastatic melanoma cell line identifies osteopontin as a new lymphangiogenic factor. Int. J. Oncol. 41, 1455\u20131463 (2012).","journal-title":"Int. J. Oncol."},{"key":"929_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.immuni.2004.06.014","volume":"21","author":"L Ohl","year":"2004","unstructured":"Ohl, L. et al. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 21, 279\u2013288 (2004).","journal-title":"Immunity"},{"key":"929_CR38","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.immuni.2008.03.006","volume":"28","author":"N Onai","year":"2008","unstructured":"Onai, N. & Manz, M. G. The STATs on dendritic cell development. Immunity 28, 490\u2013492 (2008).","journal-title":"Immunity"},{"key":"929_CR39","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.3390\/ijms19061803","volume":"19","author":"YL Su","year":"2018","unstructured":"Su, Y. L., Banerjee, S., White, S. V. & Kortylewski, M. STAT3 in tumor-associated myeloid cells: multitasking to disrupt immunity. Int. J. Mol. Sci. 19, 1803 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"929_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0092-8674(94)90169-4","volume":"76","author":"KA Hogquist","year":"1994","unstructured":"Hogquist, K. A. et al. T cell receptor antagonist peptides induce positive selection. Cell 76, 17\u201327 (1994).","journal-title":"Cell"},{"key":"929_CR41","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.4462","volume":"6","author":"BM Arneth","year":"2018","unstructured":"Arneth, B. M. Activation of CD4 and CD8 T cell receptors and regulatory T cells in response to human proteins. PeerJ 6, e4462 (2018).","journal-title":"PeerJ"},{"key":"929_CR42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1126\/science.1136080","volume":"315","author":"D Dudziak","year":"2007","unstructured":"Dudziak, D. et al. Differential antigen processing by dendritic cell subsets in vivo. Science 315, 107\u2013111 (2007).","journal-title":"Science"},{"key":"929_CR43","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1158\/1078-0432.CCR-12-2064","volume":"19","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide, R. H. & Glennie, M. J. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19, 1035\u20131043 (2013).","journal-title":"Clin. Cancer Res."},{"key":"929_CR44","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","volume":"124","author":"A Gros","year":"2014","unstructured":"Gros, A. et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246\u20132259 (2014).","journal-title":"J. Clin. Invest."},{"key":"929_CR45","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s13238-020-00707-9","volume":"11","author":"Q Liu","year":"2020","unstructured":"Liu, Q., Sun, Z. & Chen, L. Memory T cells: strategies for optimizing tumor immunotherapy. Protein Cell 11, 549\u2013564 (2020).","journal-title":"Protein Cell"},{"key":"929_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33248-7","volume":"8","author":"J Navarro-Barriuso","year":"2018","unstructured":"Navarro-Barriuso, J. et al. Comparative transcriptomic profile of tolerogenic dendritic cells differentiated with vitamin D3, dexamethasone and rapamycin. Sci. Rep. 8, 14985 (2018).","journal-title":"Sci. Rep."},{"key":"929_CR47","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175, 984\u2013997 (2018).","journal-title":"Cell"},{"key":"929_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).","journal-title":"Genome Biol."},{"key":"929_CR49","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","volume":"176","author":"H Li","year":"2019","unstructured":"Li, H. et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 176, 775\u2013789 (2019).","journal-title":"Cell"},{"key":"929_CR50","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812\u2013830 (2018).","journal-title":"Immunity"},{"key":"929_CR51","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.12688\/f1000research.25141.1","volume":"9","author":"JA Eddy","year":"2020","unstructured":"Eddy, J. A. et al. CRI iAtlas: an interactive portal for immuno-oncology research. F1000Res 9, 1028 (2020).","journal-title":"F1000Res"},{"key":"929_CR52","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"929_CR53","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934\u2013949 (2017).","journal-title":"Cell"},{"key":"929_CR54","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy. Cancer Cell 35, 238\u2013255 (2019).","journal-title":"Cancer Cell"},{"key":"929_CR55","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"PL Chen","year":"2016","unstructured":"Chen, P. L. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827\u2013837 (2016).","journal-title":"Cancer Discov."},{"key":"929_CR56","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35\u201344 (2016).","journal-title":"Cell"},{"key":"929_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1199","volume":"13","author":"J Li","year":"2023","unstructured":"Li, J. et al. Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): a novel population in the tumour microenvironment and immunotherapy target. Clin. Transl. Med. 13, e1199 (2023).","journal-title":"Clin. Transl. Med."},{"key":"929_CR58","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3389\/fphar.2019.00377","volume":"10","author":"G Herradon","year":"2019","unstructured":"Herradon, G., Ramos-Alvarez, M. P. & Gramage, E. Connecting metainflammation and neuroinflammation through the PTN\u2013MK\u2013RPTP\u03b2\/\u03b6 axis: relevance in therapeutic development. Front. Pharmacol. 10, 377 (2019).","journal-title":"Front. Pharmacol."},{"key":"929_CR59","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1084\/jem.20181102","volume":"216","author":"LT Weckbach","year":"2019","unstructured":"Weckbach, L. T. et al. Midkine drives cardiac inflammation by promoting neutrophil trafficking and NETosis in myocarditis. J. Exp. Med. 216, 350\u2013368 (2019).","journal-title":"J. Exp. Med."},{"key":"929_CR60","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.4049\/jimmunol.1102346","volume":"188","author":"Y Sonobe","year":"2012","unstructured":"Sonobe, Y. et al. Midkine inhibits inducible regulatory T cell differentiation by suppressing the development of tolerogenic dendritic cells. J. Immunol. 188, 2602\u20132611 (2012).","journal-title":"J. Immunol."},{"key":"929_CR61","doi-asserted-by":"publisher","first-page":"6592","DOI":"10.4049\/jimmunol.174.11.6592","volume":"174","author":"SH Naik","year":"2005","unstructured":"Naik, S. H. et al. Cutting edge: generation of splenic CD8+ and CD8\u2013 dendritic cell equivalents in FMS-like tyrosine kinase 3 ligand bone marrow cultures. J. Immunol. 174, 6592\u20136597 (2005).","journal-title":"J. Immunol."},{"key":"929_CR62","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012924","volume":"13","author":"D Olmeda","year":"2021","unstructured":"Olmeda, D. et al. Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics. EMBO Mol. Med. 13, e12924 (2021).","journal-title":"EMBO Mol. Med."},{"key":"929_CR63","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.immuni.2015.05.018","volume":"42","author":"J Helft","year":"2015","unstructured":"Helft, J. et al. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c+MHCII+ macrophages and dendritic cells. Immunity 42, 1197\u20131211 (2015).","journal-title":"Immunity"},{"key":"929_CR64","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/bioinformatics\/btp101","volume":"25","author":"G Bindea","year":"2009","unstructured":"Bindea, G. et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped Gene Ontology and pathway annotation networks. Bioinformatics 25, 1091\u20131093 (2009).","journal-title":"Bioinformatics"},{"key":"929_CR65","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).","journal-title":"BMC Bioinformatics"},{"key":"929_CR66","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico, A. et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 44, e71 (2016).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00929-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00929-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00929-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T06:02:23Z","timestamp":1745820143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00929-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":66,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["929"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-00929-y","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"17 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}